Adiponectin levels and risk of coronary heart disease: A meta-analysis of prospective studies

American Journal of the Medical Sciences

Volumn 345, Issue 6, 2013, Pages 455-461

  Zhang, Huan ^a   Mo, Xingbo ^a   Hao, Yongchen ^a   Huang, Jianfeng ^a   Lu, Xiangfeng ^a   Cao, Jie ^a   Gu, Dongfeng ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Adiponectin; Coronary heart disease; Meta analysis; Prospective studies

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CREATININE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

AGE; ALCOHOL CONSUMPTION; BLOOD PRESSURE; CARDIOVASCULAR RISK; CONFERENCE PAPER; CREATININE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNICITY; FAMILY HISTORY; FOLLOW UP; GENDER; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL RECORD REVIEW; META ANALYSIS; MIDDLE AGED; PHYSICAL ACTIVITY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SMOKING; WAIST HIP RATIO;

EID: 84878455972     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318262dbef     Document Type: Conference Paper

References (40)

1. Pajvani UB, Du X, Combs TP, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 2003;278: 9073-85.
2. Stefan N, Stumvoll M. Adiponectin - its role in metabolism and beyond. Horm Metab Res 2002;34:469-74.
3. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277:25863-6.
4. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473-6.
5. Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000;96:1723-32.
6. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000;102:1296-301.
7. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103:1057-63.
8. Arita Y, Kihara S, Ouchi N, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002;105:2893-8.
9. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-5.
10. Kazumi T, Kawaguchi A, Hirano T, et al. Serum adiponectin is associated with high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men. Metabolism 2004;53:589-93.
11. Iwashima Y, Katsuya T, Ishikawa K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004;43: 1318-23.
12. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291: 1730-7.
13. Koenig W, Khuseyinova N, Baumert J, et al. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol 2006;48:1369-77.
14. Kizer JR, Barzilay JI, Kuller LH, et al. Adiponectin and risk of coronary heart disease in older men and women. J Clin Endocrinol Metab 2008;93:3357-64.
15. Lawlor DA, Davey Smith G, Ebrahim S, et al. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 2005; 90:5677-83.
16. Sattar N, Wannamethee G, Sarwar N, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006;114:623-9.
17. Kanaya AM, Wassel Fyr C, Vittinghoff E, et al. Serum adiponectin and coronary heart disease risk in older Black and White Americans. J Clin Endocrinol Metab 2006;91:5044-50.
18. Laughlin GA, Barrett-Connor E, May S, et al. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol 2007;165:164-74.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
20. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical-epidemiology/oxford. htm. Accessed September 19, 2011.
21. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
22. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002;21:1539-58.
23. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
24. Lindsay RS, Resnick HE, Zhu J, et al. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol 2005;25:e15-6.
25. Schulze MB, Shai I, Rimm EB, et al. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005;54: 534-9.
26. Hatano Y, Matsumoto M, Ishikawa S, et al. Plasma adiponectin level and myocardial infarction: the JMS Cohort Study. J Epidemiol 2009;19: 49-55.
27. Cote M, Cartier A, Reuwer AQ, et al. Adiponectin and risk of coronary heart disease in apparently healthy men and women (from the EPIC-Norfolk Prospective Population Study). Am J Cardiol 2011;108: 367-73.
28. Pischon T, Hu FB, Girman CJ, et al. Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women. Atherosclerosis 2011;219:322-9.
29. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001;98:2005-10.
30. Berg AH, Combs TP, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-53.
31. Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002;277:37487-91.
32. Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002;106:2767-70.
33. Rothenbacher D, Brenner H, Marz W, et al. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 2005;26:1640-6.
34. Otsuka F, Sugiyama S, Kojima S, et al. Hypoadiponectinemia is associated with impaired glucose tolerance and coronary artery disease in non-diabetic men. Circ J 2007;71:1703-9.
35. Koz C, Uzun M, Yokusoglu M, et al. Evaluation of plasma adiponectin levels in young men with coronary artery disease. Acta Cardiol 2007;62:239-43.
36. Lu G, Chiem A, Anuurad E, et al. Adiponectin levels are associated with coronary artery disease across Caucasian and African-American ethnicity. Transl Res 2007;149:317-23.
37. Zhang BC, Liu WJ, Che WL, et al. Serum total adiponectin level and risk of cardiovascular disease in Han Chinese populations: a meta-analysis of 17 case-control studies. Clin Endocrinol (Oxf) 2012;77:370-8.
38. Teoh H, Strauss MH, Szmitko PE, et al. Adiponectin and myocardial infarction: a paradox or a paradigm? Eur Heart J 2006;27:2266-8.
39. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006;116:1784-92.
40. Tsao TS, Murrey HE, Hug C, et al. Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement- related protein of 30 kDa (Acrp30). J Biol Chem 2002;277: 29359-62.